mirvetuximab
immunogen
['ovarian']
#asco23 in a study, ovarian cancer patients treated with elahere lived for a median of 16.5 months compared to just under 13 months for those treated with standard chemotherapy. 
Reporting from the frontiers of health & medicine. 
Sign up for any of our 10 free newsletters here: https://t.co/CBx3GZBv31